Skip to main content
Profound Medical Corp. logo

Profound Medical Corp. — Investor Relations & Filings

Ticker · PROF ISIN · CA74319B5027 US Manufacturing
Open in API
Filings indexed 260 across all filing types
Latest filing 2019-09-28 Capital/Financing Update
Country US United States of America
Listing US PROF

About Profound Medical Corp.

https://profoundmedical.com/

Profound Medical Corp. is a commercial-stage medical technology company that develops and markets incision-free therapies for ablative interventions. The company's primary platform, TULSA-PRO®, combines real-time Magnetic Resonance (MR) imaging with robotically-driven, transurethral thermal ultrasound and closed-loop temperature feedback. This system is designed for the precise and customizable ablation of prostate tissue from the inside-out. It is used to treat various conditions, including localized prostate cancer and benign prostatic hyperplasia (BPH). The technology enables physicians to create customized treatment plans and monitor tissue temperature in real-time, aiming to maximize efficacy while preserving patient quality of life.

Recent filings

Filing Released Lang Actions
FORM F-10
Capital/Financing Update Classification · 95% confidence The document is a Form F-10 Registration Statement filed with the U.S. Securities and Exchange Commission under the Securities Act of 1933. It is a registration statement for securities offerings, including common shares, warrants, and units, with a maximum aggregate offering price of $100 million. The text includes detailed information about the offering, the prospectus, and the plan of distribution. This type of filing is related to capital raising and financing activities rather than financial results, management changes, or other report types. Therefore, it fits the category of Capital/Financing Update filings.
2019-09-28 English
RW
Regulatory Filings Classification · 100% confidence The document is a letter from Profound Medical Corp. to the SEC requesting withdrawal of a previously filed Registration Statement (Form 20FR12B) related to a proposed Nasdaq listing. It does not contain financial data, audit information, or detailed report content. Instead, it is a regulatory communication about the withdrawal of a filing and future intentions to file a new registration statement. The document length is short (1790 characters), and it is clearly an announcement or request rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory communications that do not fit other specific categories.
2019-09-23 English
20FR12B
Annual Report Classification · 100% confidence The document is a Form 20-F filing with the SEC, which is an annual report filed by foreign private issuers. It includes detailed sections such as financial statements, operating and financial review, directors and management information, major shareholders, and other comprehensive disclosures typical of an annual report. The presence of IFRS accounting standards and the detailed table of contents further confirm this is a full annual report. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the correct classification is Annual Report (10-K equivalent for foreign issuers).
2019-08-29 English
Regulatory Filings 2017
Regulatory Filings
2017-10-05 English
Regulatory Filings 2017
Regulatory Filings
2017-10-05 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.